History of Fine Chemical Business

  • *The Pharmaceuticals & Fine Chemicals Business inherited the chemical business operations of our former company Daiichi Pure Chemicals.
1947 Daiichi Pure Chemicals Co., Ltd. established on July 10th.
The Yanagishima Plant started to manufacture hydrosulfite, lactic acid, and ethyl lactate.
1948 Started to manufacture sulfosalicylic acid, an in vitro diagnostic.
1953 Started to manufacture ZONON®, a metal chelator.
1954 Started to manufacture para-aminosalicylic acid, an API.
1958 Started to manufacture and market amino acids. Acquired patent related to the manufacturing of amino acids.
1960 Construction of the Funabori Factory completed.
1969 Started to manufacture L-DOPA.
1973 Acquired land in Hachimantai (then known as Matsuo-mura), Iwate Prefecture.
1977 Agreement on environmental pollution control concluded with Hachimantai (Matsuo-mura), Iwate Prefecture.
1978 Construction of Iwate Plant (Stage 1) completed. Acquired Dowa Kasei Kogyo.
1979 Iwate Plant inaugurated.
1981 Construction of Iwate Plant (Stage 2) completed.
1984 Underwent first FDA inspection.
1985 Funabori Plant closed and production transferred to the Iwate Plant.
Construction of Iwate Plant (Stage 3) completed.
1992 Construction of the Iwate Plant and anaerobic wastewater treatment facility completed.
1994 Daiichi Pure Chemical Quality Assurance Charter enacted.
2000 Construction of Iwate Plant (Stage 4) completed.
2001 Iwate Plant acquired IS014001 certification.
2004 Iwate Plant IS014001 certification renewed.
2006 Construction of Iwate Plant (Stage 5) completed.
2007 Iwate Plant IS014001 certification renewed.
2008 Merger of Daiichi Pure Chemical chemical business and Sekisui Chemical medical business. Came into operation as the Sekisui Medical Co. Ltd. Pharmaceuticals & Fine Chemicals Business
Underwent EDQM inspection.
2011 Expanded contract manufacturing of peptide pharmaceuticals.
Underwent our 9th FDA inspection (in October).
2012 Gave presentations about our peptide manufacturing technologies at events such as TIDES.
2013 Added a cleanroom for investigational new drugs and peptides.
2014 Installed preparative HPLC equipment and a freeze dryer in the cleanroom.
2016 Underwent 10th FDA inspection (in June).
2017 Underwent 11th FDA inspection (in July).
Added a clean room for medium volume GMP-compliant manufacturing (in September)
2018 Added a building for API manufacturing.